Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,547JPY
18 Apr 2014
Price Change (% chg)

¥1 (+0.02%)
Prev Close
¥4,546
Open
¥4,542
Day's High
¥4,560
Day's Low
¥4,525
Volume
1,174,100
Avg. Vol
3,119,840
52-wk High
¥5,520
52-wk Low
¥4,180

4502.T

Chart for 4502.T

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer... (more)

Overall

Beta: 0.64
Market Cap (Mil.): ¥3,590,678.00
Shares Outstanding (Mil.): 789.68
Dividend: 90.00
Yield (%): 3.96

Financials

  4502.T Industry Sector
P/E (TTM): 34.78 33.26 33.35
EPS (TTM): 130.73 -- --
ROI: 3.11 19.66 18.92
ROE: 4.65 20.35 19.68
Search Stocks

Update-Moody's affirms Takeda's Aa3 rating: outlook stable

For the full text of this story please click the following link:

09 Apr 2014

Japan drugmaker Takeda to fight $6 billion damages awarded by U.S. jury

SAN FRANCISCO/TOKYO - Takeda Pharmaceutical Co Ltd said it would contest $6 billion in punitive damages imposed by a jury in the United States in a case that accused Japan's largest drugmaker of concealing cancer risks associated with its Actos diabetes drug.

08 Apr 2014

UPDATE 4-Japan drugmaker Takeda to fight $6 bln damages awarded by U.S. jury

* Louisiana jury orders $6 bln damages from Takeda, $3 bln from Eli Lilly

08 Apr 2014

Japan drugmaker Takeda to fight $6 billion damages imposed by U.S. jury

SAN FRANCISCO/TOKYO - Takeda Pharmaceutical Co Ltd said it would contest $6 billion in punitive damages imposed by a U.S. federal jury in a case alleging that Japan's largest drugmaker had concealed cancer risks associated with its Actos diabetes drug.

08 Apr 2014

Nikkei drops to 2-week low as Takeda drags down pharma sector

TOKYO, April 8 - Japanese shares fell 1.4 percent to a two-week low on Tuesday as Takeda Pharmaceutical Co tumbled after a U.S. jury ordered it to pay $6 billion over claims it concealed risks associated with its Actos diabetes drug. Gains in the yen also hurt sentiment, while tech stocks extended declines into a second day. During the session, the Bank of Japan stood pat on policy as expected after a two-day policy meeting. The Nikkei share average lost 201.97 points to

08 Apr 2014

U.S. jury orders Takeda, Eli Lilly to pay $9 bln damages in Actos case -lawyer

April 8 - A U.S. jury ordered Takeda Pharmaceutical Co Ltd to pay $6 billion in punitive damages and Eli Lilly and Co to pay $3 billion in a case claiming that cancer risks to the diabetes drug Actos were concealed, the plaintiffs' lawyer said.

08 Apr 2014

Takeda shares drop after report on $6 billion jury award over Actos

TOKYO - Shares in Takeda Pharmaceutical Co Ltd were down nearly 6 percent on Tuesday morning after Bloomberg news reported that a U.S. jury ordered it to pay $6 billion in punitive damages in a case claiming it hid cancer risks of its Actos diabetes drug.

07 Apr 2014

Takeda shares drop after report on $6 bln jury award over Actos

TOKYO, April 8 - Shares in Takeda Pharmaceutical Co Ltd were down nearly 6 percent on Tuesday morning after Bloomberg news reported that a U.S. jury ordered it to pay $6 billion in punitive damages in a case claiming it hid cancer risks of its Actos diabetes drug.

07 Apr 2014

Japan's Takeda, Dainippon get EU nod for schizophrenia drug

TOKYO, March 31 - Takeda Pharmaceutical Co Ltd and Dainippon Sumitomo Pharma Co Ltd said on Monday the European Commission had given them marketing authorisation for Latuda, a once-a-day oral treatment for schizophrenia in adults.

30 Mar 2014

EU backs J&J hepatitis C pill plus new drugs from Lilly, Takeda

LONDON - European regulators have recommended approval of a new pill for hepatitis C from Johnson & Johnson, underscoring the rapid development of oral treatment options for the liver-destroying disease.

21 Mar 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks